Antidepressants for cognitive impairment in schizophrenia — A systematic review and meta-analysis

Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis

“…We present a detailed outline and discussion of all related systematic reviews and meta-analyses (56) in the online data supplement (see Tables S25-S33). In summary, four of these smaller reviews showed statistically nonsignificant effect sizes with wide confidence intervals, but the specific standardized mean differences were nevertheless similar to ours (21,22,26,29). Three other meta-analyses presented statistically significant findings in favor of antidepressants, almost exactly matching results from some of our analyses, but with much smaller sample sizes (25,27,28).…”

“…Recent narrative reviews did not answer these crucial questions and delivered unclear conclusions (1,19,20). Crucially, previous systematic reviews and meta-analyses addressed only specific subgroups of patients with schizophrenia or particular adjunctive medications (cognitive impairment [21], negative symptoms [22][23][24][25], postpsychotic depression [26], add-on noradrenergic and specific serotonergic antidepressants ajp in Advance ajp.psychiatryonline.org 1 …”

“…Recent narrative reviews did not answer these crucial questions and delivered unclear conclusions (1,19,20). Crucially, previous systematic reviews and meta-analyses addressed only specific subgroups of patients with schizophrenia or particular adjunctive medications (cognitive impairment [21], negative symptoms [22][23][24][25], postpsychotic depression [26], add-on noradrenergic and specific serotonergic antidepressants [27], add-on fluvoxamine [28], and add-on mirtazapine or mianserin [29]), resulting in inclusion of a limited number of studies (mean number of trials=13; range: 5 to 26). Two of these systematic reviews did not find some beneficial effect of adjunctive antidepressants on psychopathology (21,23).…”

The rationale for antidepressants in the treatment of schizophrenia: A modern view on the problem in the context of evidence-based medicine

“…[37] в ме-таанализе более двух десятков исследований, свидетельст-вуют о доказанности эффективности терапии флуоксети-ном, ритансерином 6 и тразадоном и недоказанности эффек-тивности применения миртазапина, ребоксетина, миансе-рина, циталопрама, флувоксамина, пароксетина и сертра-лина (хотя недоказанность их эффективности может быть связана с недостаточным числом рандомизированных кон-тролируемых исследований -РКИ). Интерес вызывают данные еще одного метаанализа, опубликованного в сентя-бре 2014 г. североамериканскими психиатрами [39]. Его ре-зультаты свидетельствуют об отсутствии доказательств эф-фективности циталопрама, флувоксамина, миртазапина, дулоксетина, миансерина, бупропиона и ребоксетина при лечении больных с «когнитивными нарушениями» (т. е. симптомами, которые в отечественной психиатрии тради-ционно расцениваются как проявление негативных рас-стройств).…”

Evaluation of association of common variants in HTR1A and HTR5A with schizophrenia and executive function

“…The association between the 5-HT system and cognitive dysfunction has been investigated in SCZ patients in some recent studies394041, but HTR1A and HTR5A have not yet been evaluated. Given of the heterogeneous nature of SCZ and inconsistent findings from genetic association studies of SCZ, the use of endophenotypes to refine the SCZ phenotype has been advocated42.…”